# Effectiveness and Safety of a Single-Center Clinical Study on a CD25 Monoclonal Antibody-Containing GVHD Prophylaxis Scheme to Reduce the Incidence of Severe Acute GVHD After Umbilical Cord Blood Transplantation for Malignant Hematologic Diseases

> **NCT06480630** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Anhui Provincial Hospital** · enrollment: 39 (estimated)

## Conditions studied

- Acute Graft Versus Host Disease
- Malignant Hematologic Neoplasm

## Interventions

- **DRUG:** Basiliximab

## Key facts

- **NCT ID:** NCT06480630
- **Lead sponsor:** Anhui Provincial Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-07-01
- **Primary completion:** 2026-06-30
- **Final completion:** 2027-06-30
- **Target enrollment:** 39 (ESTIMATED)
- **Last updated:** 2024-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06480630

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06480630, "Effectiveness and Safety of a Single-Center Clinical Study on a CD25 Monoclonal Antibody-Containing GVHD Prophylaxis Scheme to Reduce the Incidence of Severe Acute GVHD After Umbilical Cord Blood Transplantation for Malignant Hematologic Diseases". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06480630. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*